"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

For more information on each ETRACS ETN, see “List of ETNs”. b “Current Yield (annualized)” equals the current quarterly Coupon Amount, multiplied by four (to annualize such coupon), divided by the ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. HealthDay News — For patients with inadequately controlled type 2 diabetes ...

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

At week 40, the change from baseline in HbA1c was −1.44 and −0.67 percent with tirzepatide and dulaglutide escalation to 4.5 mg or maximum tolerated dose, respectively. HealthDay News — For patients ...

The company said Tuesday it now provides access to Zepbound, a brand-name version of the drug tirzepatide, as well as to generic liraglutide. Zepbound is made by drugmaker Eli Lilly. While Hims & Hers ...

Recent research has highlighted the potential benefits of switching from dulaglutide to tirzepatide for patients with type 2 diabetes who have not achieved adequate control of their condition. The ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...

Hims & Hers now provides access to Zepbound, a brand-name version of the drug tirzepatide, for $1,899 per month. HealthDay News — The telehealth company Hims & Hers Health is expanding its weight-loss ...

General practitioners will be able to prescribe the weight loss injection tirzepatide (Mounjaro) to “prioritised patient cohorts” from 23 June, NHS England has said. New interim commissioning guidance ...

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of branded versions of Eli Lilly’s (NYSE:LLY) popular weight loss therapy ...